The Department of Justice has issued Merck & Co
The subpoena, which Merck disclosed in its quarterly securities filing, involves the brain cancer drug Temodar, hepatitis C medicine Peg-Intron, and Intron A, which is approved for hepatitis C as well as for forms of cancer.
The subpoena seeks information from January 2004 to the present in a federal health care investigation under criminal statutes, Merck said in its filing. The company said it is cooperating with the probe.
(Reporting by Lewis Krauskopf, editing by Gerald E. McCormick)